Type 1 diabetes (T1D) arises from autoimmune-mediated destruction of insulin-producing \( \beta \)-cells leading to impaired insulin secretion and hyperglycemia. T1D is accompanied by DNA damage, oxidative stress, and inflammation, although there is still scarce information about the oxidative stress response and DNA repair in T1D pathogenesis. We used the microarray method to assess mRNA expression profiles in peripheral blood mononuclear cells (PBMCs) of 19 T1D patients compared to 11 controls and identify mRNA targets of microRNAs that were previously reported for T1D patients. We found 277 differentially expressed genes (220 upregulated and 57 downregulated) in T1D patients compared to controls. Analysis by gene sets (GSA and GSEA) showed an upregulation of processes linked to ROS generation, oxidative stress, inflammation, cell death, ER stress, and DNA repair in T1D patients. Besides, genes related to oxidative stress responses and DNA repair (\( \text{PTGS2, ATF3, FOSB, DUSP1, and TNFAIP3} \)) were found to be targets of four microRNAs (hsa-miR-101, hsa-miR-148a, hsa-miR-27b, and hsa-miR-424). The expression levels of these mRNAs and microRNAs were confirmed by qRT-PCR. Therefore, the present study on differential expression profiles indicates relevant biological functions related to oxidative stress response, DNA repair, inflammation, and apoptosis in PBMCs of T1D patients relative to controls. We also report new insights regarding microRNA-mRNA interactions, which may play important roles in the T1D pathogenesis.
1. Introduction

Type 1 diabetes (T1D) or insulin-dependent diabetes mellitus (IDDM) is a polygenic disorder possibly triggered by environmental factors that results from a T cell-mediated autoimmune attack against the insulin-producing β-cells localized in the pancreatic islets of Langerhans [1]. The typical pathological lesion is a destructive immune cell infiltrate (insulitis), affecting insulin-producing β-cells at several levels and impairing insulin synthesis as a consequence [2]. During this process, islet-infiltrating mononuclear cells release pro-inflammatory cytokines and specific biochemical markers in the serum of patients, which have been exploited as potential markers for the pathogenesis of T1D. In fact, the levels of inflammatory markers have been significantly upregulated in T1D patients compared to healthy human subjects [3].

The hallmark of T1D is a decreased insulin secretion that is subsequently succeeded by chronic hyperglycemia, which has been implicated in long-term complications affecting several organs, including the kidneys, eyes, heart, nerves, and blood vessels [4]. Chronic hyperglycemia induces the production of reactive oxygen species (ROS), which in excess can overwhelm the antioxidant system and lead to oxidative stress [5, 6]. There is evidence that oxidative stress can increase the release of proinflammatory cytokines, subsequently leading to inflammation and β-cell destruction, contributing to T1D progression [7]. Nevertheless, studies have reported that T1D patients present elevated oxidative stress markers [8–10] and decreased antioxidant capacity [7, 9, 11]. Besides, T1D patients have shown higher levels of DNA damage and oxidative DNA damage than controls [12, 13], indicating that DNA repair mechanisms may be compromised in those patients. However, there is still scarce information about molecular signaling pathways and genes implicated in biological processes related to oxidative stress responses and DNA repair in T1D.

Moreover, there are reports that point out to mRNA-microRNA interactions that might be involved in T1D pathogenesis [14, 15]. In fact, since microRNAs act as gene expression regulators, they might play some roles in the pathogenesis of human diseases. The miR-21 increased β-cell apoptosis through degradation of mRNA BCL2 transcript in mouse models of T1D and human cells [16]. By inhibiting GLP-1 expression, the miR-192 inhibits insulin secretion [17]. Other differentially expressed microRNAs have been implicated in β-cell dysfunction, apoptosis [18], insulin secretion impairment [19], and inflammatory processes [20] through mRNA interactions. Some microRNAs are found consistently upregulated (miR-24-3p, miR-148a-3p, miR-181a-5p, miR-210-5p, and miR-375) or downregulated (miR-146a-5p, miR-150-5p, miR-342-3p, miR-1275, and miR-100-5p) in T1D patients compared to nondiabetic controls [14]. Still, there is much to clarify about the role of microRNAs in T1D development.

In the present study, we applied the microarray method to study the mRNA transcript expression profiles displayed by peripheral blood mononuclear cells (PBMCs) of T1D patients compared to healthy subjects. We also aimed to identify potential mRNAs targets that are mainly associated with responses to oxidative stress and DNA repair pathways and those associated with differentially expressed microRNAs (that were previously reported by Takahashi et al. [21]).

2. Material and Methods

2.1. Study Subjects. A total of 19 patients with type 1 diabetes (7 women and 12 men, with age ranging from 18 to 37), recruited while undergoing regular follow-up at the outpatient Endocrinology of the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto (HC/FMRP-USP), Brazil, and 11 healthy subjects (control group) (6 women and 5 men, with age ranging from 20 to 31) participated in the present study. The main characteristics of all participants are described in Tables 1 and 2. All patients were receiving treatment with human insulin, and those presenting recent episodes of ketoacidosis and late diabetic complications were excluded from the study. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Local Ethics Committee of Clinical Hospital–Ribeirão Preto Medical School, University of São Paulo (protocol code no. 13314/2011 in November 23, 2011). Informed written consent was obtained from all participants.

2.2. Sample Collection, Isolation of Peripheral Blood Mononuclear Cells (PBMCs), and RNA Extraction. Peripheral blood samples (20 mL) were collected from all participants, followed by isolation of PBMCs using Histopaque-1077 (Sigma-Aldrich, Inc., USA). Total RNA was extracted using Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to manufacturer’s instructions. The quality and quantification of RNA samples were measured using the NanoDrop ND-1000 Spectrophotometer (Uniscience, São Paulo, Brazil). The integrity of RNA samples was evaluated using Agilent RNA Nano 6000 chips onto the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA samples that were protein- and phenol-free, and RNA integrity number (RIN) ≥ 7.0 were considered for the microarray and qRT-PCR analysis.

2.3. mRNA/miRNA Microarrays and qRT-PCR. The microarray technique and the expression data normalization and statistical analysis were performed as previously described [21, 22]. The microarray data from all samples used in this study are publicly available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under the accession numbers E-MEXP-3348 (T1D group) and E-MEXP-3963 (control group). The qRT-PCR method was used to validate the expression results obtained for mRNA and microRNA microarrays. For microRNA expression level analysis, 10 ng of total RNA was reverse transcribed using Taqman microRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA). The qRT-PCR was performed using Taqman Universal PCR Master Mix with AmpErase uracil N-glycosylase (UNG) (Applied Biosystems) and Taqman MicroRNA Assays (Applied Biosystems) for the following microRNAs: hsa-miR-101 (MIMAT0000099) (002253), hsa- miR-148a (MIMAT0000243) (000470), hsa-miR-27b (MIMAT0000419) (000409), hsa-miR-424 (MIMAT0001341)
For mRNA expression levels, one μg of total RNA was reverse transcribed using Superscript III First-Strand Synthesis System (Invitrogen) after DNAse (Invitrogen) treatment. The qRT-PCR was performed using Taqman Universal PCR Master Mix with AmpErase uracil N-glycosylase (UNG) (Applied Biosystems) and Taqman Gene Expression Assays (Applied Biosystems) for ATF3 (Hs00231069_m1), TNFAIP3 (Hs00234713_m1), PTGS2 (Hs00153133_m1), UCP3 (Hs01106052_m1), DUSP1 (Hs00610256_g1), FOSB (Hs00171851_m1), GAPDH (Hs02758991_g1), and HPRT1 (Hs02800695_m1). For both microRNA and mRNA, the reactions were carried out in triplicate in 96-well plates, sealed with MicroAmp® Optical Adhesive Film, and performed on a StepOnePlus Real-Time PCR System (Applied Biosystems). The microRNA and mRNA expression levels were obtained according to the $2^{-\Delta\Delta Ct}$ method [23]. To analyze the expression levels, both groups of patients and controls were subjected to the normality test D'Agostino-Pearson omnibus K2 followed by the Mann–Whitney. The F-test was also used to test the group variances, followed by the T-test for unpaired samples with Welch’s correction. P values < 0.05 were considered statistically significant in the comparisons.

### Table I: Main clinical characteristics of type 1 diabetes (T1D) patients.

| Patient   | Age (years) | Sex | Duration of T1D (years) | Insulin                  | Fasting glucose levels (mg/dL) | HbA1c (%) | HLA-DQBI   |
|-----------|-------------|-----|-------------------------|--------------------------|-------------------------------|-----------|------------|
| T1D_01    | 36          | M   | 11                      | NPH 24 + 16 UI; regular 13 UI | 213                           | 10.8      | *0302      |
| T1D_02    | 23          | M   | 13                      | Lanthus 28 UI; Lispro 4 + 2 + 2 UI | 197                           | 8.3       | *0301      |
| T1D_03    | 24          | M   | 6                       | NPH 36 + 30 UI; regular 6 + 4 UI | 260                           | 10        | *0302      |
| T1D_04    | 18          | M   | 8                       | NPH 28 + 24 UI; regular 10 + 10 UI | 23                            | 7.2       | *0201      |
| T1D_05    | 23          | M   | 20                      | NPH 50 + 30 UI; regular 12 + 6 + 6 UI | 178                           | 10.1      | *0202      |
| T1D_06    | 21          | F   | 8                       | Ultrafast 42 + 6 UI       | 223                           | 7.8       | *0301      |
| T1D_07    | 29          | M   | 2                       | NPH 20 + 12 UI; regular 6 UI | 59                            | 11.1      | *0301      |
| T1D_08    | 30          | M   | 14                      | NPH 36 + 36 UI; regular 10 + 10 UI | 47                            | 8.9       | *0201      |
| T1D_09    | 21          | M   | 16                      | NPH 54 + 10 UI; regular 8 + 10 UI | 66                            | 9         | *0301      |
| T1D_10    | 28          | F   | 5                       | NPH 34 + 22 UI            | 193                           | 12.5      | *0501      |
| T1D_11    | 29          | M   | 3                       | NPH 24 + 12 UI; regular 4 UI | 225                           | 9.8       | *0302      |
| T1D_12    | 27          | F   | 10                      | NPH 24 + 12 UI; regular 6 + 6 UI | 257                           | 10.4      | *0201      |
| T1D_13    | 37          | F   | 7                       | Lanthus 44 UI; Aspart 4 + 5 + 2 UI | 82                            | 8.4       | *0501      |
| T1D_14    | 24          | F   | 14                      | Lanthus 34 UI; regular 5 + 7 + 7 UI | 293                           | 8.5       | *0302      |
| T1D_15    | 22          | F   | 13                      | NPH 40 + 20 UI            | 143                           | 8.3       | *0303      |
| T1D_16    | 18          | M   | 5                       | NPH 20 + 10 + 15 UI; regular 10 + 8 + 8 UI | 60                            | 9.5       | *0301      |
| T1D_17    | 25          | F   | 6                       | NPH 66 + 6 UI; regular 4 + 8 + 14 UI | 85                            | 10.5      | *0301      |
| T1D_18    | 23          | M   | 11                      | Glagina 34 UI; Aspart 4 + 6 + 6 UI | 123                           | 10.3      | *0301      |
| T1D_19    | 25          | M   | 8                       | Levemir 20 + 20 UI        | 162                           | 7.7       | *0301      |

1Patients whose samples were used in the microRNA expression study. It is noteworthy that all the 19 samples were used in the analysis of mRNA expression data. 2Patients using metformin (850 mg).

(000604), and RNU48 (001006). For mRNA expression levels, one μg of total RNA was reverse transcribed using Superscript III First-Strand Synthesis System (Invitrogen) after DNAse (Invitrogen) treatment. The qRT-PCR was performed using Taqman Universal PCR Master Mix with AmpErase uracil N-glycosylase (UNG) (Applied Biosystems) and Taqman Gene Expression Assays (Applied Biosystems) for ATF3 (Hs00231069_m1), TNFAIP3 (Hs00234713_m1), PTGS2 (Hs00153133_m1), UCP3 (Hs01106052_m1), DUSP1 (Hs00610256_g1), FOSB (Hs00171851_m1), GAPDH (Hs02758991_g1), and HPRT1 (Hs02800695_m1). For both microRNA and mRNA, the reactions were carried out in triplicate in 96-well plates, sealed with MicroAmp® Optical Adhesive Film, and performed on a StepOnePlus Real-Time PCR System (Applied Biosystems). The microRNA and mRNA expression levels were obtained according to the $2^{-\Delta\Delta Ct}$ method [23]. To analyze the expression levels, both groups of patients and controls were subjected to the normality test D’Agostino-Pearson omnibus K2 followed by the Mann–Whitney. The F-test was also used to test the group variances, followed by the T-test for unpaired samples with Welch’s correction. P values < 0.05 were considered statistically significant in the comparisons.

2.4. Gene Set Analysis (GSA) and Gene Set Enrichment Analysis (GSEA). The analysis of gene sets was performed
using BRB-ArrayTools (developed by Richard Simon and BRB-ArrayTools Development Team) to identify gene groups with significant expression (GSA) and significantly enriched gene sets (GSEA), according to Gene Ontology (GO) terms. The LS/KS permutation test and Efron-Tibshirani’s GSA maxmean test with random 1,000 permutations were carried out with a threshold of 0.005 to filter statistically significant (GSA) and significantly enriched (GSEA) gene sets, respectively.

3. Results

After normalization and adjustment of data, the analysis performed by rank products revealed 277 differentially expressed genes (DEGs) in PBMCs of patients with T1D compared to controls (220 upregulated and 57 downregulated) (Table S1). Some of these genes have already been widely described as associated with T1D, including those related to inflammatory processes (Table 3).

In addition, the GSA and GSEA analysis indicated 49 significantly expressed gene sets ($p < 0.005$) and 55 statistically enriched gene sets ($p < 0.005$) in PBMCs of T1D patients compared to the control group. Biological processes related to apoptosis (apoptotic signaling pathway, release of cytochrome c from mitochondria), oxidative stress (regulation of oxidoreductase activity), inflammatory processes (interleukin-2 production), and cell death (positive regulation of neuron death) were found significantly upregulated in T1D patients. Pathways associated with endoplasmic reticulum stress and unfolded protein response (response to endoplasmic reticulum stress, cellular response to topologically incorrect protein/unfolded protein), reactive nitrogen species (nitric oxide metabolic and biosynthetic process), and DNA repair (double-strand break repair via homologous recombination and recombinational repair) were found statistically enriched for T1D patients (Figures 1(a) and 1(b)). The complete list of significant and statistically enriched gene sets can be found in Table S2.

Besides, to identify genes that were specifically related to the biological processes “response to oxidative stress” (GO: 0006979) and “DNA repair” (GO: 0006281), the list of DEGs was submitted to the gene prioritization tool Endeavor, which allowed the integration of the results in several gene databases. The 16 best ranked genes in each process and the respective fold-change values are highlighted (Table 4).

We also verified whether any of those 277 DEGs were included as possible targets for the 44 differentially expressed microRNAs ($\text{AUC} \geq 0.90$), which were previously reported for the same group of patients [21] using the VENNY tool. We found 144 (52%) genes that may be potentially regulated by the differentially expressed microRNAs. Of these, 75 are possibly regulated by the upregulated microRNAs, seven by the downregulated microRNAs, and 62 by both up- and downregulated microRNAs (Table 5). Interestingly, among the possible targets, nine and thirteen genes belong to “response to oxidative stress” and “DNA repair” biological processes, respectively, such as UCP3, PTGS2, ATF3, FOSB, DUSP1, and TNFAIP3 genes.

To confirm the expression of some mRNAs, we selected six genes (UCP3, PTGS2, ATF3, FOSB, DUSP1, and

Table 2: Main characteristics of healthy individuals (control group).

| Controls | Sex | Age (years) | Fasting glucose levels (mg/dL) | HLA DQB1 |
|----------|-----|-------------|-------------------------------|----------|
| CO_01$^1$ | M   | 28          | 92                            | $^*$03:01 |
| CO_02$^1$ | F   | 25          | 86                            | $^*$02:01 |
| CO_03$^1$ | F   | 27          | 88                            | $^*$03:01 |
| CO_04$^1$ | F   | 26          | 90                            | $^*$04:02 |
| CO_05$^1$ | M   | 25          | 94                            | $^*$02:01 |
| CO_06$^1$ | F   | 29          | 82                            | $^*$03:01 |
| CO_07$^1$ | M   | 20          | 87                            | $^*$02:01 |
| CO_08$^1$ | F   | 20          | 87                            | $^*$06:03 |
| CO_09$^1$ | M   | 26          | 81                            | $^*$03:01 |
| CO_10     | M   | 22          | 97                            | $^*$05:01 |
| CO_11     | F   | 31          | 93                            | $^*$03:01 |

$^1$Controls whose samples were used for the study of microRNA expression profiles. All 11 samples were used in the analysis of mRNA expression data.
Table 3: List of differentially expressed genes, which have been widely related to T1D in the literature, in peripheral blood mononuclear cells (PBMCs) of T1D patients compared to the control group.

| Gene | Gene name | Functions | FC | FDR |
|------|------------|-----------|----|-----|
| IL1B | Interleukin 1, beta | Immune and inflammatory response, upregulation of T cell proliferation | 2.60 | 0.00E + 00 |
| TNF  | Tumor necrosis factor | Humoral and inflammatory immune response, activation of MAPK activity | 2.30 | 2.21E – 02 |
| CXCL2 | Chemokine (C-X-C motif) ligand 2 | Inflammatory and immune response, chemotaxis | 2.22 | 0.00E + 00 |
| CCL20 | Chemokine (C-C motif) ligand 20 | Inflammatory and immune response, chemotaxis | 1.70 | 7.00E – 04 |
| PTX3 | Pentraxin 3, long | Inflammatory response, phagocytosis and biosynthetic process of nitric oxide upregulation | 1.62 | 0.00E + 00 |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cylooxygenase) | Cell cycle regulation, response to cytokine stimulation and oxidative stress, biosynthetic process of prostaglandin | 1.57 | 0.00E + 00 |
| TNFAIP3 | Tumor necrosis factor, alpha-induced protein 3 | Antiapoptosis, negative regulation of NF-κB transcription factor activity, TNF production, and inflammatory response | 1.44 | 0.00E + 00 |
| ATF3 | Activating transcription factor 3 | Transcription regulation | 1.40 | 3.40E – 03 |
| DUSP2 | Dual specificity phosphatase 2 | Inactivation of MAPK activity, regulation of the apoptotic process | 1.38 | 0.00E + 00 |
| IL6 | Interleukin 6 (interferon, beta 2) | Humoral immune response, regulation of cell proliferation | 1.37 | 4.00E – 04 |
| BCL2A1 | BCL2-related protein A1 | Antiapoptosis | 1.27 | 3.00E – 04 |
| GZMB | Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | Cytolysis, proteolysis, apoptotic process | 1.22 | 5.40E – 03 |
| IFNG | Interferon, gamma | Humoral and adaptive immune response, response to unfolded proteins of the endoplasmic reticulum, apoptotic process | 1.17 | 2.87E – 02 |
| GZMH | Granzyme H (cathepsin G-like 2, protein h-CCPX) | Cytolysis, proteolysis, apoptotic process | 1.16 | 1.60E – 03 |
| CD69 | CD69 molecule | Lymphocyte proliferation, signal transmission receptor | 1.14 | 3.16E – 02 |
| HLA-DQB1 | Major histocompatibility complex, class II, DQ beta 1 | Immune response, upregulation of antigen processing and presentation | 0.90 | 5.80E – 03 |

The functions of all genes were obtained by the SOURCE tool (2000) (http://puma.princeton.edu/cgi-bin/source/sourceResult); FC: fold change; FDR: false discovery rate.
Figure 1: Biological processes that were found as differentially expressed/enriched in peripheral blood mononuclear cells (PBMCs) of T1D patients compared to the control group. (a) Gene set analysis (GSA) showing the first 15 biological processes related to significantly expressed genes in T1D patients compared to controls. (b) Gene set enrichment analysis (GSEA) showing the first 15 biological processes linked to significantly enriched genes in T1D patients compared to the controls. Only biological processes with $p < 0.005$ are shown.
Table 4: Differentially expressed genes (with their respective fold-change values) obtained for PBMCs of T1D patients compared with the control group, highlighting genes belonging to the GO terms “response to oxidative stress” and “DNA repair,” according to the analysis performed by the Endeavor tool.

| Rank | Oxidative stress response | Gene name | Fold change | DNA repair | Gene name | Fold change |
|------|---------------------------|-----------|-------------|------------|-----------|-------------|
| 1    | DUSP1                     | Dual specificity phosphatase 1 | 1.43        | GADD45B    | Growth arrest and DNA-damage-inducible, beta | 1.25        |
| 2    | UCP3                      | Uncoupling protein 3 (mitochondrial, proton carrier) | 0.81        | JUNB       | Jun B protooncogene | 1.15        |
| 3    | PFKL                      | Phosphofructokinase, liver | 1.14        | PFKL       | Phosphofructokinase, liver | 1.14        |
| 4    | PTGS2                     | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 1.57        | ATF3       | Activating transcription factor 3 | 1.40        |
| 5    | PDGFRB                    | Platelet-derived growth factor receptor, beta polypeptide | 1.15        | FOSB       | FBJ murine osteosarcoma viral oncogene homolog B | 1.43        |
| 6    | CCL4                      | Chemokine (C-C motif) ligand 4 | 1.75        | PDGFRB     | Platelet-derived growth factor receptor, beta polypeptide | 1.15        |
| 7    | CCR2                      | Chemokine (C-C motif) receptor 2 | 0.80        | FOS        | FBJ murine osteosarcoma viral oncogene homolog | 1.12        |
| 8    | LTF                       | Lactotransferrin | 0.97        | DDX3Y      | DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked | 1.19        |
| 9    | CCL2                      | Chemokine (C-C motif) ligand 2 | 1.18        | CDKN1C     | Cyclin-dependent kinase inhibitor 1C (p57, Kip2) | 1.16        |
| 10   | MYOM2                     | Myomesin 2 | 0.87        | PPP1R15A   | Protein phosphatase 1, regulatory subunit 15A | 1.49        |
| 11   | LPL                       | Lipoprotein lipase | 1.31        | DUSP1      | Dual specificity phosphatase 1 | 1.43        |
| 12   | DSP                       | Desmoplakin | 1.10        | TNFAIP3    | Tumor necrosis factor, alpha-induced protein 3 | 1.44        |
| 13   | CES1                      | Carboxylesterase 1 | 0.84        | MAPK8IP1   | Mitogen-activated protein kinase 8 interacting protein 1 | 0.89        |
| 14   | PPP1R15A                  | Protein phosphatase 1, regulatory subunit 15A | 1.49        | NFKBIA     | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 1.58        |
| 15   | TNFAIP3                   | Tumor necrosis factor, alpha-induced protein 3 | 1.44        | LPL        | Lipoprotein lipase | 1.31        |
| 16   | HP                        | Haptoglobin | 1.12        | DDX43      | DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 | 1.09        |
Table 5: Potential microRNA-mRNA interactions selected from both lists of differentially expressed targets in PBMCs of T1D patients compared to controls.

| Genes | MicroRNAs |
|-------|-----------|
| DUSP1 | hsa-let-7f; hsa-let-7g; hsa-miR-32; hsa-miR-98; hsa-miR-101; hsa-miR-148a; hsa-miR-148b |
| UCP3  | hsa-let-7f; hsa-let-7g; hsa-miR-18b; hsa-miR-19a; hsa-miR-20b; hsa-miR-98; hsa-miR-148a; hsa-miR-148b; hsa-miR-454; hsa-miR-548c-3p; hsa-miR-931a; hsa-miR-324-5p |
| PTGS2 | hsa-miR-7; hsa-miR-26b; hsa-miR-33a; hsa-miR-101; hsa-miR-148a; hsa-miR-148b; hsa-miR-542-3p; hsa-miR-548c-3p |
| PDGFRB| hsa-miR-18b; hsa-miR-19a; hsa-miR-20b; hsa-miR-338-3p; hsa-miR-342-3p; hsa-miR-423-5p; hsa-miR-766 |
| CCL4  | hsa-miR-542-3p |
| CCL2  | hsa-miR-33a; hsa-miR-335 |
| LPL   | hsa-miR-18b; hsa-miR-26b; hsa-miR-32; hsa-miR-342-3p |
| DSP   | hsa-miR-186; hsa-miR-548c-3p |
| TNFAIP3| hsa-let-7f; hsa-let-7g; hsa-miR-18b; hsa-miR-19a; hsa-miR-21; hsa-miR-27b; hsa-miR-98; hsa-miR-186; hsa-miR-548c-3p; hsa-miR-424; hsa-miR-423-5p |
| GADD45B| hsa-miR-454; hsa-miR-301a |
| JUNB  | hsa-miR-101; hsa-miR-338-3p |
| ATF3  | hsa-miR-7; hsa-miR-16; hsa-miR-27b; hsa-miR-195; hsa-miR-199a-3p; hsa-miR-542-3p; hsa-miR-424; hsa-miR-342-3p |
| FOSB  | hsa-miR-27b; hsa-miR-148a; hsa-miR-148b; hsa-miR-338-3p; hsa-miR-548c-3p; hsa-miR-301a; hsa-miR-424; hsa-miR-342-3p; hsa-miR-342-5p; hsa-miR-423-5p; hsa-miR-766; hsa-miR-940 |
| FOS   | hsa-miR-7; hsa-miR-26b; hsa-miR-101; hsa-miR-199a-3p; hsa-miR-338-3p |
| CDKN1C| hsa-miR-32 |
| MAPK8IP1| hsa-miR-10a; hsa-miR-338-3p; hsa-miR-542-3p; hsa-miR-940 |
| DDX43 | hsa-miR-548c-3p |
| NFKBIA| hsa-miR-140-3p |
Figure 2: Relative expression of genes associated with oxidative stress response and DNA repair in PBMCs of T1D patients compared to the control group, evaluated by qRT-PCR. For all genes, the assay was performed for 19 T1D samples and 10 control samples. For FOSB (d), two controls were excluded (Co_01 and Co_11). These samples were the same used for the microarray method. Two endogenous genes were used to normalize the expression values: GAPDH and HPRT1. For the UCP3 (a), PTGS2 (b), ATF3 (c), FOSB (d), and DUSP1 (e), bars represent the median and interquartile range. For the TNFAIP3 (f), bars represent the mean ± standard deviation. * indicates statistically significant values for $p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ns: not significant.
Figure 3: Comparison of fold change values (T1D versus control group), obtained by the microarrays and qRT-PCR methods, for the selected differentially expressed mRNAs.

Figure 4: Relative expression of microRNAs evaluated by qRT-PCR, whose predicted targets are associated with oxidative stress response and DNA repair processes in PBMCs of T1D patients compared to the control group. The assay was performed for 11 samples of T1D patients and nine controls, which were the same used for the microarray method. Expression values of (a) hsa-miR-101, (b) hsa-miR-148a, (c) hsa-miR-27b, and (d) hsa-miR-424 were normalized by the endogenous RNU48 gene. The bars represent the mean ± standard deviation. ** indicates statistically significant values for $p < 0.01$; *** $p < 0.001$. 
hsa-miR-424 microRNAs: analysis) by performing the qRT-PCR for the following four microRNA expression (obtained in the microarray analysis). In addition, a series of genes highlighted in this study were differentially expressed microRNAs. The same samples (11 T1D patients and nine controls) were used for both methods.

TNFAIP3) to perform analysis by qRT-PCR. Five genes, except UCP3, were significantly upregulated in T1D patients compared to the controls, similarly as we have found in the microarray experiments. UCP3 expression was not significantly different between patients and controls (Figures 2(a)–2(f) and 3).

Regarding the expression of microRNAs, we confirmed the microRNA expression (obtained in the microarray analysis) by performing the qRT-PCR for the following four microRNAs: hsa-miR-101, hsa-miR-148a, hsa-miR-27b, and hsa-miR-424. All of them were significantly upregulated in T1D patients compared to the controls, compatible with the results obtained by the microarray method [21] (Figures 4(a)–4(d) and 5).

4. Discussion

The exact cause of T1D has not yet been elucidated, thus requiring a search for potential disease biomarkers and their possible functions related to the molecular mechanisms associated with the disease, providing new insights towards their application in clinical practice.

Among the 277 differentially expressed genes, it is important to note that we found some genes (HLA-DQB1, CD69, and TNFAIP3) that have been reported to be implicated in the pathogenesis of T1D [24]. While HLA-DQB1 was downregulated, CD69 and TNFAIP3 were found upregulated. In addition, a series of genes highlighted in this study are involved in molecular and cellular events associated with T1D (IL1B, TNF, IFNG, GZMB, and GZMH) [25, 26] and inflammatory processes (IL1B, IFNG, IL6, PTX3, CCL20, CXCL2, and DUSP2) [3, 27], endorsing other studies in the literature. Interestingly, our results indicated differential expression of genes related to T1D even years after diagnosis, such as CCL3L3, CCL4, CXCL1, CXCL3, and IL8 genes.

In addition, the analysis by gene sets (GSA and GSEA) revealed an upregulation of biological processes related to ROS generation, oxidative stress, inflammation, cell death, ER stress, and DNA repair, among others. The excessive generation of reactive species (derived from oxygen or nitrogen) leads to a redox imbalance in the organism. Consequently, oxidative stress disturbs endoplasmic reticulum (ER) homeostasis and activates the unfolded protein response (UPR). Oxidative stress can also increase DNA damage, which may activate DNA repair and, depending on the scenario, may also lead to apoptosis [28, 29]. Other studies have described upregulation of DNA repair, inflammation, ER-stress response, and apoptosis pathways in T1D patients [30, 31]. There is also evidence that oxidative stress and inflammation occur even several months before the onset of T1D in children, favoring the autoimmunity and induced cellular damage in β-cells [32].

In this study, the high expression levels of DUSP1, PTGS2, TNFAIP3, ATF3, and FOSB genes in T1D compared with the control group were identified by the microarray analysis and confirmed by the qRT-PCR method. DUSP1 (dual-specificity protein phosphatase-1), also known as MKP1, encodes a phosphatase protein that dephosphorylates and inactivates MAPKs (mitogen-activated protein kinases), playing an essential role in cell proliferation, cellular growth, inflammation, cell cycle arrest, innate immune function, and cellular response to oxidative damage [33]. In fact, it has been shown an upregulation of DUSP1 under stress conditions that lead to apoptosis [34]. The gene PTGS2 (prostaglandin synthase cyclooxygenase 2) encodes cyclooxygenase 2 (COX2) that generates prostaglandin E2 (PGE2). Stress conditions such as hyperglycemia and ROS induce the expression of PTGS2 increasing PGE2 levels, which further stimulate ROS production [35, 36]. Elevated expression of PTGS2 is commonly observed in many chronic inflammatory diseases, and high COX2 levels are also associated with microvascular complications of diabetes, including endothelial dysfunction and renal injuries [37].

TNFAIP3 (tumor necrosis factor (TNF) α-induced protein-3) encodes a zinc finger protein (A20), which inhibits NFKB signaling, decreases NO production, and has demonstrated a critical role in protecting β-cells from apoptosis [38–40]. Interestingly, we found an upregulation of NFKB Inhibitor Alpha (NFKBIA) and NFKB Inhibitor Zeta (NFKBIZ) genes, both with inhibitory functions upon NFKB, which may be related to the high level of inflammation in T1D patients [41]. TNFAIP3 has also been indicated as a candidate gene for T1D [42]. Some authors suggest that the SNP rs2327832 of TNFAIP3 may help to predict glycemic control and disease progression in T1D children [39].

ATF3 (activating transcription factor 3) gene is an adaptive-response gene activated upon various stress stimuli, including ROS, DNA damage, genotoxic agents, and cytokines [43]. There is evidence that ATF3 silencing increases apoptosis in β-cells, thus suggesting a protective role regarding antiapoptotic effects [44]. ATF3 also represses inflammatory responses (by inhibiting NFKB), several proinflammatory cytokines, and NO synthesis [45].

Regarding FOSB (FosB Proto-Oncogene, AP-1 Transcription Factor Subunit), this gene encodes leucine zipper proteins that form dimers with other proteins (e.g., Jun and ATF/CREB) to compose the AP-1 complex which plays a crucial role in DNA repair mechanism [46]. Altogether,
the upregulation of the aforementioned genes in T1D group may indicate that T1D patients exhibit an adaptive response activating cellular stress response and DNA repair genes upon several conditions, such as ROS, DNA damage, oxidative stress, and inflammation.

Moreover, microRNAs are important posttranscriptional regulators of several biological processes in T1D patients. Notably, it has been demonstrated that microRNAs show a specific signature for each form of diabetes (T1D, type 2 diabetes, or gestational diabetes) [47] and may be implicated in the pathogenesis and complications of diabetes [48]. Therefore, we crossed our differentially expressed mRNAs with the set of 44 differentially expressed microRNAs, which were previously reported for the same group of T1D patients [21]. Our results indicated that 52% of differentially expressed genes are predicted targets of the 44 microRNAs. Those target genes are related to inflammation, stress response, and DNA repair, showing the importance of microRNA regulation in these processes. In this study, we also confirmed the expression of four microRNAs (hsa-miR-101, hsa-miR148a, hsa-miR-27b, and hsa-miR-424) by qRT-PCR, all of them being upregulated in PBMCs of T1D patients.

miR-101 has been found to regulate DNA-dependent protein kinase (DNA-PKcs) and ATM (ataxia telangiectasia mutated) gene, with roles in suppressing DNA repair processes and sensitizes cells to DNA damage induction [49]. Besides, there is evidence confirming that miR-101 targets DUSP1, promoting the activation of MAPks and stimulating the production of proinflammatory cytokines [50]. On the other hand, miR-101 targets PTGS2, decreasing the release of proinflammatory cytokines [51]. miR-101 is also related to cytokine-mediated defective insulin production [52], β-cell dysfunction [52, 53], and increased apoptosis [52]. Interestingly, upregulation of miR-101 has been found in individuals with normal glucose levels, but testing positive for autoantibodies linked to T1D, suggesting that miR-101 precede the impairment of glucose homeostasis and may represent a potential biomarker for the onset of T1D [53]. In addition, miR-101 downregulation ameliorates insulin release and protects β-cells from cytokine-induced apoptosis [52].

Overexpression of miR-27b was found to inhibit NRF2 activation, a master regulator of antioxidant response [54], and suppress NFkB activation [55]. Furthermore, mir-27b upregulation has been associated with the onset of retinopathy [56], while its downregulation has been implicated in glucose tolerance impairment [57] and nephropathy [58]. The upregulation of mir-148a has been consistently found in T1D patients [59, 60]. miR-148a has been described as a regulator of autoimmunity, β-cell tolerance [18], and insulin activity [61]. Recently, Tamara et al. [62] reported that upregulation of miR-424 in T1D patients was associated with increased levels of inflammatory cytokines and increased risk of cardiovascular diseases.

Altogether, our results indicate specific mRNA and microRNA expression profiles in PBMCs from T1D patients relative to healthy nondiabetic individuals. In addition, we have shown that a number of biological processes related to oxidative stress response, DNA repair, inflammation, and apoptosis are upregulated in T1D patients. Besides, we provide new data regarding potential microRNA-mRNA interactions in T1D, in particular involving genes associated with responses to oxidative stress and DNA repair, which might play relevant roles in the microRNA-target network in T1D patients.

Data Availability

The microarray data from all samples used in this study are publicly available in the ArrayExpress database under the accession numbers (https://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-3348 and https://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-3963).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

E.A.D., G.A.P., and E.T.S.H. did the conceptualization. P.T., D.J.X., A.F.E., C.V.A.C., and D.M.R. did the formal analysis. E.A.D., G.A.P., and E.T.S.H. acquired funding. P.T., D.J.X., A.F.E., C.V.A.C., M.C.F.F., and D.M.R. conducted the research, collected the samples and performed the experiments. M.C.F.F., E.A.D., G.A.P., and E.T.S.H. provided the resources. M.C.F.F., E.A.D., G.A.P., and E.T.S.H. supervised the research. P.T., D.J.X., J.E.B.F.L., and E.T.S.H. were responsible for writing—original draft. J.E.B.F.L. and E.T.S.H. were responsible for writing—review and editing. All authors have read and agreed to the published version of the manuscript. All authors contributed to and approved the final manuscript.

Acknowledgments

This research was funded by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Brazil (protocol numbers: 2008/56594-8, 2010/12069-7, 2010/05622-1, and 2013/09352-7); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil)-Finance Code 001; and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil, protocol no. 309854/2017-2).

Supplementary Materials

Table S1: differentially expressed genes in PBMCs from T1D patients compared to control group obtained in mRNA microarray experiments. Table S2: differentially expressed/enriched biological processes in PBMCs from T1D patients compared to the control group obtained using BRB-ArrayTools. (Supplementary Materials)

References

[1] L. A. DiMeglio, C. Evans-Molina, and R. A. Oram, “Type 1 diabetes,” Lancet, vol. 391, pp. 2449–2462, 2018.
[2] T. L. Van Belle, K. T. Coppeters, and M. G. Von Herrath, "Type 1 diabetes: etiology, immunology, and therapeutic strategies," *Physiological Reviews*, vol. 91, pp. 79–118, 2011.

[3] N. Fatima, S. M. Faisal, S. Zubair et al., "Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects," *PLoS One*, vol. 11, no. 8, article e0161548, 2016.

[4] International Diabetes Federation IDF, *Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 9th ed edition, 2019.

[5] G. S. Dave and K. Kalia, "Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy," *Cellular and Molecular Biology*, vol. 53, article e0161548, pp. 68–78, 2007.

[6] B. Poljsak, D. Šuput, and I. Milišav, "Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants," *Oxidative Medicine and Cellular Longevity*, vol. 2013, 2013.

[7] M. Nassima, A. A. Djamila, G. Baya, and M. Hafida, "Oxidative stress biomarkers during type 1 diabetes in Algerian children," *Clinical Biochemistry*, vol. 47, pp. 776–777, 2014.

[8] M. T. Goodarzi, A. A. Navidi, M. Rezaei, and H. Babahmadi-Rezaei, "Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes," *Journal of Clinical Laboratory Analysis*, vol. 24, pp. 72–76, 2010.

[9] P. Codoñer-Franch, A. B. López-Jaén, A. De La Mano-Herrández, E. Sentandreu, R. Simó-Jordá, and V. Valls-Bellés, "Oxidative markers in children with severe obesity following low-calorie diets supplemented with mandarin juice," *Acta Paediatrica*, vol. 99, pp. 1841–1846, 2010.

[10] A. Altincik, B. Tuğlu, K. Demir, G. Çaţli, A. Abaci, and E. Böber, "Relationship between oxidative stress and blood glucose fluctuations evaluated with daily glucose monitoring in children with type 1 diabetes mellitus," *Journal of Pediatric Endocrinology & Metabolism*, vol. 29, pp. 435–439, 2016.

[11] A. Pastore, P. Ciampalini, G. Tozzi et al., "All glutathione forms are depleted in blood of obese and type 1 diabetic children," *Pediatric Diabetes*, vol. 13, pp. 272–277, 2012.

[12] M. P. A. Hannon-Fletcher, M. J. O’Kane, K. W. Moles, C. Weatherup, C. R. Barnett, and Y. A. Barnett, "Levels of peripheral blood cell DNA damage in insulin dependent diabetes mellitus human subjects," *Mutation Research/DNA Repair*, vol. 460, no. 1, pp. 53–60, 2000.

[13] Y. Dinçer, T. Akçay, H. Ilkova, Z. Alademir, and G. Özbay, "DNA damage and antioxidant defense in peripheral leukocytes of patients with type 1 diabetes mellitus," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 527, no. 1-2, pp. 49–55, 2003.

[14] T. S. Assmann, M. Recamonde-Mendoza, B. M. De Souza, and D. Crispim, "MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis," *Endocrine Connections*, vol. 6, pp. 773–790, 2017.

[15] K. Margaritis, G. Margioula-iaroukou, S. Giza et al., "MicroRNA implications in type-1 diabetes mellitus: a review of literature," *International Journal of Molecular Sciences*, vol. 22, no. 22, pp. 12165, 2021.

[16] E. K. Sims, A. J. Lakhter, E. Anderson-Baucum, T. Kono, X. Tong, and C. Evans-Molina, "MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells," *Diabetologia*, vol. 60, pp. 1057–1065, 2017.

[17] W. Pan, Y. Zhang, C. Zeng, F. Xu, J. Yan, and J. Weng, "MiR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression," *Experimental and Therapeutic Medicine*, vol. 16, pp. 2717–2724, 2018.

[18] A. Gonzalez-Martin, B. D. Adams, M. Lai et al., "The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity," *Nature Immunology*, vol. 17, pp. 433–440, 2016.

[19] P. Aghu and W. R. Carthew, "MicroRNA-mediated regulation of glucose and lipid metabolism," *Nature Reviews. Molecular Cell Biology*, vol. 22, no. 6, pp. 425–438, 2021.

[20] F. J. Sheedy, E. Palsson-McDermott, E. J. Hennessy et al., "Negative regulation of TLR4 via targeting of the pro-inflammatory tumor suppressor PDCD4 by the microRNA miR-21," *Nature Immunology*, vol. 11, no. 2, pp. 141–147, 2010.

[21] P. Takahashi, D. J. Xavier, A. F. Evangelista et al., "MicroRNA expression profiling and functional annotation analysis of their targets in patients with type 1 diabetes mellitus," *Gene*, vol. 539, pp. 213–224, 2014.

[22] D. J. Xavier, P. Takahashi, A. F. Evangelista et al., "Assessment of DNA damage and mRNA/miRNA transcriptional expression profiles in hyperglycemic versus non-hyperglycemic patients with type 2 diabetes mellitus," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 776, pp. 98–110, 2015.

[23] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method," *Methods*, vol. 25, pp. 402–408, 2001.

[24] D. M. Nyaga, M. H. Vickers, C. Jeffries, J. K. Perry, and J. M. O'Sullivan, "The genetic architecture of type 1 diabetes mellitus," *Molecular and Cellular Endocrinology*, vol. 477, pp. 70–80, 2018.

[25] E. R. Podack, D. M. Lowrey, M. Lichtenheld, and A. Hamed, "Function of granule perform and esterases in T cell-mediated Reactions," *Annals of the New York Academy of Sciences*, vol. 532, pp. 292–302, 1988.

[26] L. E. Padgett, K. A. Broniowska, P. A. Hansen, J. A. Corbett, and H. M. Tse, "The role of reactive oxygen species and pro-inflammatory cytokines in type 1 diabetes pathogenesis," *Annals of the New York Academy of Sciences*, vol. 1281, pp. 16–35, 2013.

[27] R. C. Padmos, N. C. Schloot, H. Beyer et al., "Distinct monocytic gene-expression profiles in autoimmune diabetes," *Diabetes*, vol. 57, pp. 2768–2773, 2008.

[28] E. C. Kaizer, C. L. Glaser, D. Chaussabel, J. Banchereau, and J. K. Perry, "Gene expression in peripheral blood mononuclear cells from children with diabetes," *The Journal of Clinical Endocrinology and Metabolism*, vol. 92, pp. 3705–3711, 2007.

[29] A. M. Westbrook, B. Wei, J. Braun, and R. H. Schiestl, "Intestinal mucosal inflammation leads to systemic genotoxicity in mice," *Cancer Research*, vol. 69, pp. 4827–4834, 2009.

[30] M. L. Caramori, Y. Kim, A. B. Gold et al., "Differential gene expression in diabetic nephropathy in individuals with type 1 diabetes," *The Journal of Clinical Endocrinology and Metabolism*, vol. 100, pp. E876–E882, 2015.

[31] J. Gastol, A. Polus, M. Biela et al., "Specific gene expression in type 1 diabetic patients with and without cardiac
autonomic neuropathy,” *Scientific Reports*, vol. 10, no. 1, pp. 1–8, 2020.

[32] L. Balzano-Nogueira, R. Ramirez, T. Zamkovaya et al., “Integrative analyses of TEDDY omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes,” *Genome Biology*, vol. 22, p. 39, 2021.

[33] J. Shen, Y. Zhang, H. Yu et al., “Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy,” *Cancer Medicine*, vol. 5, pp. 2061–2068, 2016.

[34] Y. X. Liu, J. Wang, J. Guo, J. Wu, H. B. Lieberman, and Y. Yin, “DUSP11s controlled by p53 during the cellular response to oxidative stress,” *Molecular Cancer Research*, vol. 6, no. 4, pp. 624–633, 2008.

[35] C. Jessen, J. K. C. Kreß, A. Baluapuri et al., “The transcription factor Nrf2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression,” *Oncogene*, vol. 39, pp. 6841–6850, 2020.

[36] S. Kiritoshi, T. Nishikawa, K. Sonoda et al., “Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy,” *Diabetes*, vol. 52, pp. 2570–2577, 2003.

[37] M. Muñoz, A. Sánchez, M. Pilar Martínez et al., “COX-2 is involved in vascular oxidative stress and endothelial dysfunction of renal interlobar arteries from obese Zucker rats,” *Free Radical Biology & Medicine*, vol. 48, pp. 79–90, 2010.

[38] D. Liuwantara, M. Elliott, M. W. Smith et al., “Nuclear Factor-kB regulates β-cell Death,” *Diabetes*, vol. 55, no. 9, pp. 2491–2501, 2006.

[39] M. Fukaya, C. A. Brorssen, K. Meyerovich et al., “A20 inhibits β-cell apoptosis by multiple mechanisms and predicts residual β-cell function in type 1 diabetes,” *Molecular Endocrinology*, vol. 30, pp. 48–61, 2016.

[40] S. T. Grey, M. B. Arvelo, W. Hasenkamp, F. H. Bach, and C. Ferran, “A20 inhibits cytokine-induced apoptosis and nuclear factor-kB-dependent gene activation in islets,” *The Journal of Experimental Medicine*, vol. 190, no. 8, pp. 1135–1146, 1999.

[41] A. F. Evangelista, C. V. A. Collares, D. J. Xavier et al., “Integrative analysis of the transcriptome profiles observed in type 1, type 2 and gestational diabetes mellitus reveals the role of inflammation,” *Genomics*, vol. 7, no. 1, pp. 1–13, 2014.

[42] J. Strøling and F. Pociot, “Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis,” *Genes (Basel)*, vol. 8, no. 2, p. 72, 2017.

[43] T. Hai, C. C. Wolford, and Y. S. Chang, “ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component?,” *Gene Expression*, vol. 15, pp. 1–11, 2010.

[44] E. N. Gurzov, J. Barthion, I. Marhfour et al., “Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation,” *Oncogene*, vol. 31, pp. 1723–1732, 2012.

[45] J. W. Kwon, H. K. Kwon, H. J. Shin, Y. M. Choi, M. A. Anwar, and S. Choi, "Activating transcription factor 3 represses inflammatory responses by binding to the p65 subunit of NF-κB," *Scientific Reports*, vol. 5, no. 1, p. 14470, 2015.

[46] M. Christmann and B. Kaina, "Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation," *Nucleic Acids Research*, vol. 41, pp. 8403–8420, 2013.

[47] C. V. Collares, A. F. Evangelista, D. J. Xavier et al., “Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients,” *Notes*, vol. 6, no. 1, 2013.

[48] J. D. Massaro, C. D. Polli, M. Costa e Silva et al., “Post-transcriptional markers associated with clinical complications in type 1 and type 2 diabetes mellitus,” *Molecular and Cellular Endocrinology*, vol. 490, pp. 1–14, 2019.

[49] D. Yan, W. L. Ng, X. Zhang et al., “Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation,” *PLOS One*, vol. 5, no. 7, 2010.

[50] Q.-Y. Zhu, Q. Liu, J.-X. Chen, K. Lan, and B.-X. Ge, “MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages,” *Journal of Immunology*, vol. 185, pp. 7435–7442, 2010.

[51] C. Lin, F. Huang, G. Shen, and A. Yiming, “MicroRNA-101 regulates the viability and invasion of cervical cancer cells,” *International Journal of Clinical and Experimental Pathology*, vol. 8, pp. 10148–10155, 2015.

[52] Y. Zheng, Z. Wang, Y. Tu et al., “MiR-101a and miR-30b contribute to inflammatory cytokine-mediated β-cell dysfunction,” *Laboratory Investigation*, vol. 95, pp. 1387–1397, 2015.

[53] A. S. Santos, E. Cunha Neto, R. T. Fukui, L. R. Ferreira, and M. E. R. Silva, “Increased expression of circulating microRNA 101-3p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes,” *Frontiers in Immunology*, vol. 10, p. 1637, 2019.

[54] W. Xu, F. Li, Z. Liu et al., “MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury,” *Oncotarget*, vol. 8, pp. 70669–70684, 2017.

[55] S. Thulasingam, C. Massilamany, A. Gangapllara et al., “miR-27b+, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells,” *Molecular and Cellular Biochemistry*, vol. 352, pp. 181–186, 2011.

[56] A. Zampetaki, P. Willett, S. Burr et al., “Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes,” *Diabetes*, vol. 65, pp. 216–227, 2016.

[57] Y. H. Jiang, Y. Y. Man, Y. Liu et al., “Loss of mir-23b/27b/24-1 cluster impairs glucose tolerance via glycolysis pathway in mice,” *International Journal of Molecular Sciences*, vol. 22, no. 2, p. 550, 2021.

[58] F. Conserva, M. Barozzino, F. Pesce et al., “Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of kidney fibrosis in diabetic nephropathy,” *Scientific Reports*, vol. 9, no. 1, pp. 1–11, 2019.

[59] L. B. Nielsen, C. Wang, K. Sørensen et al., “Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that mir-25 associates to residual beta-cell function and glycaemic control during disease progression,” *Experimental Diabetes Research*, vol. 2012, 7 pages, 2012.

[60] G. E. Griecco, D. Cataldo, E. Ceccarelli et al., “Serum levels of miR-148a and miR-21-5p are increased in type 1 diabetic patients and correlated with markers of bone strength and Metabolism,” *RNA*, vol. 4, no. 4, p. 37, 2018.
[61] T. Melkman-Zehavi, R. Oren, S. Kredo-Russo et al., “MiRNAs control insulin content in pancreatic β-cells via downregulation of transcriptional repressors,” The EMBO Journal, vol. 30, no. 5, pp. 835–845, 2011.

[62] A. Tamara, D. J. Coulson, J. S. Latief, S. Bakhashab, and J. U. Weaver, “Upregulated anti-angiogenic miR-424-5p in type 1 diabetes (model of subclinical cardiovascular disease) correlates with endothelial progenitor cells, CXCR1/2 and other parameters of vascular health,” Stem Cell Research & Therapy, vol. 12, no. 1, pp. 1–14, 2021.